+811.4%
SPYM vs GSK
+164.8%
+646.7%
-54.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -0.4% | +0.5% | -0.9% | -0.6% |
| 7D | +2.6% | +1.1% | +1.4% | +2.1% |
| 30D | -2.0% | +6.3% | -8.3% | -4.3% |
| 3M | -2.8% | +1.8% | -4.6% | -3.8% |
| 6M | +2.2% | +1.7% | +0.5% | +0.7% |
| YTD | +11.5% | +6.5% | +5.0% | +7.3% |
| 1Y | +13.5% | +9.5% | +4.0% | +8.0% |
| 3Y | +78.0% | +65.3% | +12.7% | +39.4% |
| 5Y | +73.1% | +43.7% | +29.4% | +41.1% |
| 10Y | +310.9% | +104.1% | +206.7% | +182.4% |
| All | +811.4% | +164.8% | +646.7% | +416.1% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling